{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T07:03:54Z","timestamp":1784963034643,"version":"3.55.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The objective of this study is to compare the adverse events (AEs) associated with pralsetinib and selpercatinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To evaluate the imbalance of AEs linked to pralsetinib and selpercatinib in real-world data, the reporting odds ratio (ROR) was utilized to detect potential signals of AEs. Stratified analysis was conducted to examine the differences in AEs occurring among different genders and age groups taking pralsetinib and selpercatinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>FAERS received 891 reports for pralsetinib and 569 reports for selpercatinib. Our analysis confirmed expected AEs like hypertension, fatigue, and elevated transaminase levels. Unexpected AEs such as rhabdomyolysis, myocardial injury and cognitive disorder were associated with pralsetinib, while selpercatinib was linked with pulmonary embolism, deep vein thrombosis, and pericardial effusion. The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. In contrast, the risk of AEs such as ascites, elevated alanine aminotransferase, and elevated aspartate aminotransferase caused by selpercatinib is significantly higher than that of pralsetinib. Women treated with pralsetinib experience higher rates of hypertension, pulmonary embolism, and blurred vision than men, who are more susceptible to rhabdomyolysis. Adults between 18 and 65\u00a0years are more likely to experience taste disorder, edema, and pulmonary embolism than individuals older than 65, who are particularly vulnerable to hypertension. For patients treated with selpercatinib, males demonstrate a significantly higher incidence of QT prolongation, urinary tract infection, and dysphagia. Individuals aged 18 to 65 are more likely to experience pyrexia and pleural effusion than those older than 65, who are more prone to hypersensitivity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In the clinical administration of pralsetinib and selpercatinib, it is crucial to monitor the effects of gender and age on AEs and to be vigilant for unlisted AEs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1424980","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T04:34:52Z","timestamp":1726806892000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system"],"prefix":"10.3389","volume":"15","author":[{"given":"Qiong","family":"Jie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1007\/s00204-020-02788-1","article-title":"Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis","volume":"94","author":"Andronis","year":"2020","journal-title":"Arch. Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","article-title":"FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions","volume":"27","author":"Bradford","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/CAD.0000000000001590","article-title":"Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer","volume":"35","author":"Cognigni","year":"2024","journal-title":"Anticancer Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100581","DOI":"10.1016\/j.jtocrr.2023.100581","article-title":"Salvage therapy with selpercatinib for RET-rearranged NSCLC with pralsetinib-related pneumonitis and leptomeningeal disease: a case report","volume":"4","author":"d\u2019Arienzo","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/clpt.2014.17","article-title":"Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics","volume":"95","author":"Fang","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.cllc.2023.08.006","article-title":"Selpercatinib and pralsetinib induced chylous ascites in RET-rearranged lung adenocarcinoma: a case series","volume":"24","author":"Fricke","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","article-title":"Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry","volume":"35","author":"Gautschi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jtho.2022.06.008","article-title":"Brief report: chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy","volume":"17","author":"Kalchiem-Dekel","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s10637-023-01390-3","article-title":"The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis","volume":"41","author":"Ke","year":"2023","journal-title":"Invest. New Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"101911","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.21037\/tlcr-22-916","article-title":"Rhabdomyolysis in a patient with advanced lung cancer treated with osimertinib: a case report","volume":"12","author":"Li","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/17446651.2022.2060819","article-title":"Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions","volume":"17","author":"Nacchio","year":"2022","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/10781552221147500","article-title":"An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)","volume":"29","author":"Nguyen","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2169\/internalmedicine.8168-21","article-title":"Rhabdomyolysis caused by gefitinib overdose","volume":"61","author":"Obayashi","year":"2022","journal-title":"Intern Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e15441","DOI":"10.7759\/cureus.15441","article-title":"Into the unknown: a case of new-onset cardiomyopathy in a patient treated with recently approved tyrosine kinase inhibitor, pralsetinib","volume":"13","author":"Papaila","year":"2021","journal-title":"Cureus"},{"key":"B21","doi-asserted-by":"publisher","first-page":"122131","DOI":"10.1016\/j.jchromb.2020.122131","article-title":"Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry","volume":"1147","author":"\u015eent\u00fcrk","year":"2020","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.21037\/tlcr-20-549","article-title":"Phase 1\/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)","volume":"10","author":"Takeuchi","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"105850","DOI":"10.1016\/j.phrs.2021.105850","article-title":"ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib","volume":"172","author":"Wang","year":"","journal-title":"Pharmacol. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3390\/ph14111087","article-title":"P-glycoprotein (ABCB1\/MDR1) and BCRP (ABCG2) limit brain accumulation and cytochrome P450-3A (CYP3A) restricts oral exposure of the RET inhibitor selpercatinib (RETEVMO)","volume":"14","author":"Wang","year":"","journal-title":"Pharm. (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drudis.2018.06.006","article-title":"Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management","volume":"24","author":"Wen","year":"2019","journal-title":"Drug Discov. Today"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1424980\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T04:34:55Z","timestamp":1726806895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1424980\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":28,"alternative-id":["10.3389\/fphar.2024.1424980"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1424980","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,20]]},"article-number":"1424980"}}